Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dried Leaf Artemisia (DLA) is an experimental antimalarial therapy consisting of pulverized and tableted dried leaves of the *Artemisia annua* plant. Developed by researchers at Worcester Polytechnic Institute (WPI), DLA is designed as a whole-plant alternative to purified artemisinin-based combination therapies (ACTs). The therapeutic rationale for DLA is based on the synergistic interaction between artemisinin and other phytochemicals present in the leaf, such as flavonoids and additional terpenes, which may enhance artemisinin bioavailability and slow the development of drug resistance in *Plasmodium* parasites. Clinical trials, including Phase 2 studies in the Democratic Republic of Congo, have evaluated DLA for its efficacy in clearing both the asexual stages and the transmission stages (gametocytes) of malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dried Leaf Artemisia.